Ncardia Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 55

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $51.9M

  • Investors
  • 11

Ncardia General Information

Description

Operator of a biotechnology research company intended to provide technologies to expedite drug discovery and development processes. The company uses human induced pluripotent stem cells technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates, as well as enhance cardiovascular and neural drug screening, enabling researchers to bring predictive human disease biology and accelerate discovery.

Contact Information

Website
www.ncardia.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Biopartner building 1
  • J.H. Oortweg 21
  • 2333 BD Leiden
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Biopartner building 1
  • J.H. Oortweg 21
  • 2333 BD Leiden
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ncardia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 19-Sep-2024 $51.9M Completed Generating Revenue
5. Later Stage VC 16-Nov-2021 Completed Generating Revenue
4. Later Stage VC 15-Jul-2019 Completed Generating Revenue
3. Grant 05-Jul-2019 Completed Generating Revenue
2. Later Stage VC (Series B) 17-Nov-2017 $12.4M $16.6M Completed Generating Revenue
1. Merger of Equals 18-Sep-2017 $4.25M $4.25M Completed Generating Revenue
To view Ncardia’s complete valuation and funding history, request access »

Ncardia Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class C
Class B
Class B 262,052 $44.9 $44.9 1x $44.9 18.94%
To view Ncardia’s complete cap table history, request access »

Ncardia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology research company intended to provide technologies to expedite drug discovery and development
Drug Discovery
Leiden, Netherlands
55 As of 2025

South San Francisco, CA
 

Helsinki, Finland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ncardia Competitors (121)

One of Ncardia’s 121 competitors is Maze Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Maze Therapeutics Formerly VC-backed South San Francisco, CA
Valo Therapeutics Venture Capital-Backed Helsinki, Finland
Verge Labs Venture Capital-Backed San Francisco, CA
Precigen Formerly VC-backed Germantown, MD
Orgenesis Corporation Germantown, MD
You’re viewing 5 of 121 competitors. Get the full list »

Ncardia Patents

Ncardia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3186849-A1 Closed manufacturing processes for large scale manufacturing of pluripotent stem cell derived cells Pending 23-Jul-2020
WO-2022019768-A1 Closed manufacturing processes for large scale manufacturing of pluripotent stem cell derived cells Inactive 23-Jul-2020
EP-3684917-A1 In vitro method for providing stem cell derived cardiomyocytes Inactive 22-Sep-2017
US-20210147805-A1 In vitro method for providing stem cell derived cardiomyocytes Inactive 22-Sep-2017
WO-2019059769-A1 In vitro method for providing stem cell derived cardiomyocytes Inactive 22-Sep-2017 C12N5/0657
To view Ncardia’s complete patent history, request access »

Ncardia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ncardia Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kiniciti PE-Backed Company Minority
Mibiton Venture Capital Minority
Noshaq Venture Capital Minority
Sino-German High Tech Fund Venture Capital Minority
Health ~ Holland Government
You’re viewing 5 of 11 investors. Get the full list »

Ncardia Acquisitions (3)

Ncardia’s most recent deal was a Merger/Acquisition with Celyad Oncology (Manufacturing Business Unit) for . The deal was made on 20-Sep-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Celyad Oncology (Manufacturing Business Unit) 20-Sep-2022 Merger/Acquisition Biotechnology
Axiogenesis 18-Sep-2017 Merger/Acquisition Biotechnology
Pluriomics 18-Sep-2017 Merger/Acquisition Other Pharmaceuticals and Biotechnology
To view Ncardia’s complete acquisitions history, request access »

Ncardia FAQs

  • When was Ncardia founded?

    Ncardia was founded in 2010.

  • Where is Ncardia headquartered?

    Ncardia is headquartered in Leiden, Netherlands.

  • What is the size of Ncardia?

    Ncardia has 55 total employees.

  • What industry is Ncardia in?

    Ncardia’s primary industry is Drug Discovery.

  • Is Ncardia a private or public company?

    Ncardia is a Private company.

  • What is the current valuation of Ncardia?

    The current valuation of Ncardia is .

  • What is Ncardia’s current revenue?

    The current revenue for Ncardia is .

  • How much funding has Ncardia raised over time?

    Ncardia has raised $130M.

  • Who are Ncardia’s investors?

    Kiniciti, Mibiton, Noshaq, Sino-German High Tech Fund, and Health ~ Holland are 5 of 11 investors who have invested in Ncardia.

  • Who are Ncardia’s competitors?

    Maze Therapeutics, Valo Therapeutics, Verge Labs, Precigen, and Orgenesis are some of the 121 competitors of Ncardia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process